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ABSTRACT 11-Hydroxysteroid dehydrogenase type-1
(11-HSD1) converts inert cortisone into active cortisol,
amplifying intracellular glucocorticoid action. 11-
HSD1 deficiency improves cardiovascular risk factors
in obesity but exacerbates acute inflammation. To
determine the effects of 11-HSD1 deficiency on ath-
erosclerosis and its inflammation, atherosclerosis-
prone apolipoprotein E-knockout (ApoE-KO) mice
were treated with a selective 11-HSD1 inhibitor or
crossed with 11-HSD1-KO mice to generate double
knockouts (DKOs) and challenged with an atherogenic
Western diet. 11-HSD1 inhibition or deficiency atten-
uated atherosclerosis (74–76%) without deleterious
effects on plaque structure. This occurred without
affecting plasma lipids or glucose, suggesting indepen-
dence from classical metabolic risk factors. KO plaques
were not more inflamed and indeed had 36% less T-cell
infiltration, associated with 38% reduced circulating
monocyte chemoattractant protein-1 (MCP-1) and 36%
lower lesional vascular cell adhesion molecule-1 (VCAM-
1). Bone marrow (BM) cells are key to the atheroprotec-
tion, since transplantation of DKO BM to irradiated
ApoE-KO mice reduced atherosclerosis by 51%. 11-
HSD1-null macrophages show 76% enhanced choles-
terol ester export. Thus, 11-HSD1 deficiency reduces
atherosclerosis without exaggerated lesional inflamma-
tion independent of metabolic risk factors. Selective
11-HSD1 inhibitors promise novel antiatherosclerosis
effects over and above their benefits for metabolic risk
factors via effects on BM cells, plausibly macro-
phages.—Kipari, T., Hadoke, P. W. F., Iqbal, J., Man,
T. Y., Miller, E., Coutinho, A. E., Zhang, Z., Sullivan,
K. M., Mitic, T., Livingstone, D. E. W., Schrecker, C.,
Samuel, K., White, C. I., Bouhlel, M. A., Chinetti-
Gbaguidi, G., Staels, B., Andrew, R., Walker, B. R.,
Savill, J. S., Chapman, K. E., Seckl, J. R. 11-hydroxys-
teroid dehydrogenase type 1 deficiency in bone mar-
row-derived cells reduces atherosclerosis. FASEB J. 27,
000–000 (2013). www.fasebj.org
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Chronic inflammation is a key process in atherogen-
esis, with extensive macrophage and lymphocyte inva-
sion of lesions, promoting pathogenesis (1–6). Gluco-
corticoids in high doses suppress inflammation, but
glucocorticoid pharmacotherapy (7, 8) or Cushing’s
disease (9, 10) exacerbate atherosclerosis and increase
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type 1; -SMA, -smooth muscle actin; ABCA1, ATP-binding
cassette transporter A1; ABCG1, ATP-binding cassette trans-
porter G1; AcLDL, acetylated low-density lipoprotein; APC,
allophycocyanin; ApoAI, apolipoprotein AI; ApoE, apolipopro-
tein E; BM, bone marrow; CCR2, chemokine (C-C motif)
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cardiovascular events, presumably via glucocorticoid
exacerbation of systemic cardiovascular risk factors.
11-Hydroxysteroid dehydrogenase type 1 (11-HSD1)
catalyzes regeneration of active glucocorticoids (corti-
sol, corticosterone) from inert 11-keto forms (corti-
sone, 11-dehydrocorticosterone), acting as an intracel-
lular amplifier of glucocorticoid action. 11-HSD1 is
up-regulated in adipose tissue in obesity in humans
(11) and rodents (12), leading to the notion of intra-
cellular Cushing’s syndrome of adipose tissue as a cause
of obesity and its cardiometabolic consequences. In-
deed, transgenic overexpression of 11-HSD1 in adi-
pose tissue produces local, but not systemic, glucocor-
ticoid excess and causes visceral obesity and metabolic
syndrome (13). Conversely, 11-HSD1 deficiency pro-
tects mice from the adverse metabolic consequences of
dietary obesity (14–16). A selective 11-HSD1 inhibitor
lowered blood glucose, glycated hemoglobin A1c
(HbA1c) and cholesterol in patients with type 2 diabe-
tes (17). These metabolic effects are presumed athero-
protective. Indeed in mice, a selective 11-HSD1 inhib-
itor that reduced circulating cholesterol also reduced
intra-aortic cholesterol, but this study did not address
lesion structure or, crucially, inflammation (18). An-
other inhibitor had no effect on atherosclerotic lesion
size (19). The key concern is whether or not lesions are
more inflamed or structurally vulnerable.
11-HSD1 is expressed in differentiated/activated
macrophages and lymphocytes and is up-regulated dur-
ing an inflammatory response (20–22) in which gluco-
corticoids promote macrophage phagocytosis of apo-
ptotic neutrophils (23). 11-HSD1 deficiency delays
acquisition of phagocytic competence by macrophages
and exacerbates acute inflammation, at least in some
models (21, 24, 25). Glucocorticoids, albeit in high
doses, reduce the response to vascular injury and its
associated inflammation (26), and they attenuate mi-
gration (27) and proliferation (28) of vascular smooth
muscle cells, effects contributing to plaque stability.
11-HSD1 in the vessel wall, though without effect on
the contractility of normal vessels (29), amplifies anti-
proliferative effects of glucocorticoids (30). Conversely,
glucocorticoids reduce cholesteryl ester hydrolysis and
export by macrophages (31) and inhibit formation of
fibrous tissue (32, 33), processes contributing to plaque
instability. Thus, the overall effects of 11-HSD1 defi-
ciency/inhibition on atherosclerotic plaques are uncer-
tain, with systemic metabolic improvements potentially
offset by worse lesional inflammation and changes in
lesion structure. Indeed, any role for 11-HSD1 in
inflammatory/immune cells in atherogenesis is un-
known. To address these key questions, we examined
the effects of selective pharmacological inhibition or
genetic deletion of 11-HSD1 in apolipoprotein E-
knockout (ApoE-KO) mice, a model of spontaneous
atherogenesis on high cholesterol Western diet (WD).
MATERIALS AND METHODS
Animals
All animal experiments were carried out under the auspices
of the UK Animals (Scientific Procedures) Act of 1986, and
with approval from the University of Edinburgh Ethical
Review Committee. Male, 11-HSD1/ mice congenic on
the C57BL/6J genetic background have been described pre-
viously (16). 11-HSD1/ mice were crossed with ApoE/
mice (also congenic on C57BL/6J; Charles River, Margate,
Kent, UK) to produce 11-HSD1/, ApoE/ double-
knockout (DKO) mice, 11-HSD1/, apoE/ heterozy-
gote (het) mice, and apoE/ (ApoE-KO) controls. Animals
were born in the expected mendelian ratios, and DKO and
het mice were indistinguishable from ApoE-KO mice at birth,
weaning, and in adulthood. Genotyping using tail-tip DNA
was performed as described previously (15). apoE/ geno-
typing was achieved using hot start PCR with forward (exon 3,
POS 285; 5=-AACTTACTCTACACAGGATGCC-3=) and re-
verse (exon 4 pos 869; 5=-CGTCATAGTGTCCTCCAT-
CAGTGC-3=) primers. This amplified PCR products of 584 bp
for the wild-type allele and 1500 bp for the null allele. All in
vivo experiments and ex vivo analyses were performed blind to
genotype.
Induction, detection, and quantification of atherosclerosis
The effects of short-term inhibition of 11-HSD1 on athero-
sclerosis and lesion structure were assessed. Adult (10 wk old)
male ApoE-KO mice were fed a high-cholesterol WD
(D12079B; Research Diets, New Brunswick, NJ, USA) ad
libitum, for 14 wk. For the last 8 wk of this period, mice were
TABLE 1. Primer sequences for RT-PCR primers
Accession number Gene Forward primer Reverse primer UPL probe
NM_010493.2 Icam1 cccacgctacctctgctc gatggatacctgagcatcacc 81
NM_011693.3 Vcam1 tggtgaaatggaatctgaacc cccagatggtggtttcctt 34
NM_009915.2 Ccr2 acctgtaaatgccatgcaagt tgtcttccatttcctttgatttg 27
NM_013684.2 Tbp ggcggtttggctaggttt gggttatcttcacacaccatga 107
NM_011146.3 PPAR- tgctgttatgggtgaaactctg ctgtgtcaaccatggtaatttctt 2
NM_011333.3 Ccl2 catccacgtgttggctca gatcatcttgctggtgaatgagt 62
NM_009987.3 Cx3cr1 aagttcccttcccatctgct caaaattctctagatccagttcagg 10
NM_008493.3 Lep caggatcaatgacatttcacaca gctggtgaggacctgttgat 93
NM_007393.3 Actb ctaaggccaaccgtgaaaag accagaggcatacagggaca 64
NM_010927.3 Nos2 ctttgccacggacgagac tcattgtactctgagggctgac 13
NM_020509.3 Retnla ccctccactgtaacgaagactc cacacccagtagcagtcatcc 51
NM_008625.1 Mrc1 ggacgagcaggtgcagtt caacacatcccgcctttc 47
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randomized (balanced design, n6/group) to receive either
vehicle or a selective 11-HSD1 inhibitor (compound 544
[3-(1-adamantyl)-6,7,8,9-tetrahydro-5H-(1,2,4)-triazolo[4,3-
]azepine; ref. 18]; Enamine, Kiev, Ukraine). Mice consumed
10 mg/kg/d. This dose inhibited hepatic 11-reductase
activity by 52  4% (n3) 4 h after administration by oral
gavage, consistent with previous reports (18).
To confirm specificity of action, male (4-wk or 4.5-mo-old)
DKO, het, and ApoE-KO mice were similarly fed WD or
normal chow diet for 14 wk. Body weight and food intake
were measured weekly.
Animals were killed by asphyxiation (CO2), blood was
collected, and plasma was stored at 80°C. The vascular tree
was removed and cleaned of adherent tissue, and the aortic
arch was used immediately for en face Sudan IV staining to
identify neutral lipid incorporation (34), expressed as a
percentage of the total surface area. The innominate artery
was formalin fixed, paraffin embedded, cut into serial 4-	m
sections, and stained with U.S. trichrome (UST; ref. 35).
Luminal, lesion (neointima), and medial areas of atheroscle-
rotic vessels were quantified by light microscopy with comput-
erized planimetry (MCID Basic 7.0 image analysis software;
Imaging Research, London, ON, Canada) and, where appro-
priate, expressed as a percentage of the total area within the
internal elastic laminae (IEL). The section with the maximum
cross-sectional narrowing was chosen to represent each artery
when calculating the mean area in a group. Empty spaces
within the lesion (areas of extracellular lipid or cholesterol
crystal accumulation; ref. 36) were determined, and fibrous
caps were counted (37). Serial sections at the point of
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Figure 1. Selective 11-HSD1 inhibition reduces atherosclerotic lesions in WD-fed ApoE-KO mice. A) i) On gross inspection,
lesions were evident on the lesser curvature of the aortic arch (black arrow), in the innominate artery (red arrow) and at the
origins of the left carotid and left subclavian arteries (black arrowheads). Lesions appeared to be smaller following 11-HSD1
inhibition. ii) UST demonstrated large complex lesions in the innominate artery. iii) Immunohistochemistry with -SMA
identified smooth muscle cells. iv) PSR staining identified collagen. B) Image analyses of these sections confirmed that
short-term selective 11-HSD1 inhibition reduced innominate artery atherosclerosis in ApoE-KO mice. C) 11-HSD1 inhibition
did not alter the proportion of smooth muscle cells in atherosclerotic lesions in the innominate artery of ApoE-KO mice.
However, collagen content was increased following 11-HSD1 inhibition, and smaller areas devoid of cells or collagen, probably
reflecting extracellular lipid pools, were reduced, compared with ApoE-KO controls (n6/group). Original view
40. *P 0.05
vs. vehicle control.
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maximal cross-sectional narrowing were stained with picro-
sirius red (PSR) to show collagen content; quantification of
picrosirius red staining was achieved using color deconvolu-
tion (Photoshop CS3 Extended, Adobe Systems, San Fran-
cisco, CA, USA) and expressed as a fraction of the total
neointimal area, as described previously (38). All image
analysis was performed blind to genotype or treatment.
Peritoneal inflammation
Peritonitis was induced in 12-wk-old female ApoE-KO or DKO
mice after injection of 0.3 ml of 10% sterile thioglycollate
(Sigma-Aldrich, Poole, UK). Peritoneal lavage cells were
analyzed by flow cytometry after peritoneal lavage with 5 ml of
PBS, 72 h postinjection.
Bone marrow (BM) transplantation
Ten-week-old male recipient ApoE-KO mice were housed
under specific pathogen-free conditions in individually venti-
lated cages and given Baytril antibiotic (2.5%) in the drinking
water for 1 wk before and 4 wk after BM transplantation. The
mice were lethally irradiated with 1050 rad (10.5 Gy) deliv-
ered from a GammaCell 40E (MDS Nordian, Fleuvus, Bel-
gium) with a cesium 137 source at a dose rate of 114 rad/min.
Following irradiation, the mice were tail vein injected with
5 
 107 donor BM cells prepared after flushing the femurs
and tibiae from female DKO or ApoE-KO with PBS. The mice
were allowed to recover for 6 wk, and BM chimerism was
verified by flow cytometric staining for 11-HSD1 and CD45
antigen on blood leukocytes. 11-HSD1 staining was per-
formed using 11-HSD1 sheep-derived antibody, generated
in-house (39) in combination with donkey anti-sheep second-
ary antibody (Alexa Fluor 488; Invitrogen, Paisley, UK). Cells
were fixed and permeabilized using a commercial kit (Fix and
Perm; Invitrogen), according to the manufacturer’s instruc-
tions, in order to allow for intracellular staining with the
11-HSD1 antibody. Engraftment was high [flow cytometric
analysis of BM transplanted from DKO donors to ApoE-KO
recipients (n5) indicated that 94.31.3% of circulating
leukocytes were donor derived]. The mice were then placed
on WD and were culled after 12 wk. The aortic arch and the
abdominal aorta were formalin fixed, and optical projection
tomography (OPT) analysis was used to quantify lesion and
lumen volumes of the innominate artery and of the abdom-
inal aorta. OPT scanning and quantification were performed
as described previously (38). The cross-sectional area of
innominate atherosclerotic lesions was also assessed, as above.
Immunohistochemistry
Immunohistochemistry was performed in serial sections taken at
the point of maximal cross-sectional narrowing in each artery.
Paraffin-embedded sections (4 	m) of innominate arteries were
deparaffinized, blocked with normal rabbit or goat serum,
incubated overnight (4°C) with primary antibodies against
Mac-2 (Cedarlane, Tyne & Wear, UK; 1:6000), CD3ε (Santa
Cruz Biotechnology, Santa Cruz, CA, USA; 1:750), or -smooth
muscle actin (-SMA; Sigma-Aldrich; 1:400) to detect macro-
phages, T cells, and smooth muscle cells, respectively. Antigen
retrieval was performed using Borg Decloaker (Biocare Medical,
Concord, CA, USA) as recommended by the manufacturer for
CD3. Sections were visualized with DAB substrate (Vector Lab-
oratories, Peterborough, UK) and counterstained with hematox-
ylin. Controls included a nonspecific IgG raised in the same
species as the primary antibody. Immunoreactivity for -SMA
was quantified using color deconvolution (as described for
collagen) and expressed as a fraction of the total neointimal
area, as described previously (38). Mac-2 and CD3 staining were
quantified by manually counting nuclei in areas of immunore-
activity and expressing the data as number of cells per square
millimeter of lesion. All image analysis was performed blind to
genotype.
Aortic function
Aortic ring functional responses to a vasoconstrictor (sero-
tonin) and endothelium-dependent (acetylcholine) and -in-
dependent [sodium nitroprusside (SNP)] vasorelaxants were
measured by isometric myography (29).
Plasma and serum measurements
Total plasma cholesterol and triglyceride levels were mea-
sured with assay kits (Infinity, Fisher Scientific, Loughbor-
ough, UK) and nonesterified fatty acid (NEFA) levels using
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Figure 2. 11-HSD1 deficiency reduces atherosclerotic lesions in WD-fed ApoE-KO mice. A) Atherosclerotic lesions were smaller
in the innominate arteries of 4.5-mo-old DKO mice (n10) fed high-cholesterol WD for 14 wk. Age-matched 11-HSD1/,
ApoE-KO het mice (n3) also showed significant atheroprotection compared with age-matched ApoE-KO control mice (n11).
*P  0.05, B) Lipid incorporation was also measured by en face Sudan IV staining of sections of the aortic arch. C)
Quantification of Sudan IV staining showed that DKO mice had less lipid incorporation than ApoE-KO controls. (n10–11/
group). *P  0.05, **P  0.01 vs. ApoE-KO.
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the Wako estar C kit (Alpha Laboratories, Eastleigh, UK),
according to the manufacturer’s instructions. Insulin levels
were measured by ultrasensitive mouse insulin ELISA kit
(Crystal Chem, Downers Grove, IL, USA) and glucose levels
by the glucose hexokinase reagent (Infinity; Thermo Elec-
tron, Waltham, MA, USA). Monocyte chemoattractant pro-
tein 1 (MCP-1) ELISA on serum samples was performed as
recommended (R&D Systems, Abingdon, UK). Plasma corti-
costerone levels were measured using an in-house radioim-
munoassay, as described previously (40).
RNA extraction and real-time PCR
Total RNA was extracted from macrophages (21), and levels
of specific mRNAs were measured as described previously
(41). Total RNA from mesenteric adipose tissue (without
lymph nodes) was extracted by homogenization in TRIzol
(Invitrogen). RNA was isolated from ascending aortas follow-
ing homogenization under liquid nitrogen, then TRIzol RNA
was purified using the RNeasy kit (Qiagen, Crawley, UK) and
reverse transcripted, and real-time quantitative RT-PCR (qRT-
PCR) was performed on a Roche Light Cycler 480 (Roche
Applied Science, Burgess Hill, UK). Primers (Invitrogen)
were designed to match intron-spanning probes within the
Roche Universal Probe Library for vascular cell adhesion
molecule 1 (VCAM-1), intercellular adhesion molecule-1
(ICAM-1), chemokine (C-C motif) receptor 2 (CCR2), frac-
talkine receptor (CX3CR1), -actin, leptin, inducible nitric
oxide synthase (iNOS), resistin-like molecule- (Relm-), and
mannose receptor (Table 1). The primer/probe set for MCP-1
(Mm00441242_m1) assay was commercially designed (TaqMan
Gene Expression Assays; Applied BioSystems, Cheshire, UK).
Each sample was run in triplicate. -Actin (Table 1) or TATA-
box binding protein (TBP; Mm00446973_m1; Applied Biosys-
tems) were used as internal references.
Flow cytometry
BM cells were obtained after flushing the femurs with 5 ml of
PBS. Tail-vein blood was collected into 3.9% sodium citrate.
Spleens were pressed through a 40-	m cell strainer (BD
Biosciences, Oxford, UK) to produce a single-cell suspension.
Red blood cells (RBCs) in the BM and blood were lysed with
BD lysis buffer (BD Biosciences, Oxford, Oxfordshire, UK),
and RBCs from spleens were lysed with Sigma lysis buffer
(Sigma-Aldrich). Cell suspensions were enumerated using a
NucleoCassette and a NucleoCounter NC-100 (ChemoMetec,
Allerød, Denmark). Nonspecific binding was blocked by
incubating the cells with 10% mouse serum (MS; Sigma-
Aldrich) for 10 min (4°C). Cells were stained in PBS with 10%
MS using conjugated antibodies at concentrations suggested
by the supplier, for 30 min at 4°C. After washing, flow
cytometric analyses were performed using BD FACS Calibur
or LSRFortessa Cell Analyzer (BD Biosciences). Data anal-
ysis was performed using FlowJo 8.2 software (TreeStar,
Ashland, OR, USA). Fluorescent flow-check fluorospheres
(Beckman and Coulter, High Wycombe, UK) were added
to blood, BM, and peritoneal lavage samples prior to
analysis in order to calculate the absolute number of cells.
Antibodies used were as follows. Anti-CD11b-peridinin
chlorophyll protein cyanin 5.5 (PerCPCy5.5) or -fluores-
cein isothiocyanate (FITC) (clone M1/70), anti-F4/80-
PerCPCy5.5 (clone BM8), anti-CD45-pacific blue (clone
30-F11), and anti-Ly6G-phycoerythrin-cyanine 7 (PECy7)
TABLE 2. Effect of 11-HSD1 deficiency on physiologic characteristics and metabolic parameters in ApoE-KO mice fed chow or WD for 14 wk
Chow WD
Parameter ApoE KO DKO ApoE KO DKO
Body weight (g) 33.2  1.2 (n9) 33.4.0  0.8 (n7) 35.4  0.5 (n7) 37.0  1.2 (n8)†
Food intake (g/wk) ND ND 22.9  2.0 (n11) 21.1  0.8 (n11)
Cholesterol (mM) 7.6  0.7 (n14) 12.8  1.2 (n14)* 23.1  1.9 (n8)††† 22.3  1.9 (n14)†††
Triglycerides (mM) 0.92  0.10 (n14) 0.96  0.11 (n14) 2.07  0.21 (n11)††† 1.40  0.14 (n  13)**,†
Mesenteric adipose tissue
weight (mg)
200.2  35.8 (n9) 300.7  50.4 (n7) 440.0  64.6 (n7)† 446.4  87.4 (n8)
Liver weight ratio
(mg/g BW)
56.5  3.4 (n9) 53.2  2.4 (n7) 50.9  2.9 (n7) 47.0  3.2 (n8)
Spleen weight ratio
(mg/g BW)
4.19  0.34 (n9) 3.04  0.16 (n7)* 4.03  0.51 (n7) 5.60  0.79 (n8)††
Thymus weight ratio
(mg/g BW)
1.42  0.16 (n9) 1.30  0.12 (n7) 1.32  0.10 (n7) 1.18  0.12 (n8)
Data are means  se. BW, body weight; ND, not determined. *P  0.05, **P  0.01 for effect of genotype; †P  0.05, ††P  0.01, †††P 
0.001 for effect of diet.
TABLE 3. Effect of selective 11-HSD1 inhibition in ApoE-KO mice on metabolic parameters
Parameter Vehicle 11-HSD1 inhibitor P
Cumulative weight gain (g) 1.9  .0.2 0.8  0.4* 0.03
Food intake (g/d) 8.0  0.4 7.6  0.2 0.3
Fasting plasma cholesterol (mM) 13.2  1.5 12.0  1.6 0.2
Fasting plasma triglycerides (mM) 2.04  0.04 2.15  0.06 0.2
Fasting plasma NEFA (mM) 2.7  0.3 3.0  0.5 0.6
Fasting plasma glucose (AUC) 54630  1504 50100  4448 0.4
Fasting plasma insulin (AUC) 108  15 71.6  14.7 0.1
Data are means  se; n  6/group. AUC, area under the curve. *P  0.05 vs. vehicle control.
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or -FITC (clone 1A8) were all from Biolegend (San Diego,
CA, USA). Anti-CD115 phycoerythrin (PE; clone AFS98),
anti-CD3-allophycocyanin (APC) or -PE (clone 17A2), and
anti-CD45-PerCPCy5.5 (clone 30-F11) were all from BD
Biosciences. Anti-CD4-FITC or -PerCPCy5.5 (clone RM4-5),
anti-B220-PE or -FITC (clone RA3-6B2), anti-CD25-APC
(clone PC61.5), and anti-CD8a-APC (clone 53-6.7) were all
from eBiosciences (Hatfield, UK). Anti-7/4-Alexa Fluor
647 (clone 7/4; AbD Serotec, Oxford, UK), anti-CD11c-
APC (clone N418), and anti-B220-Pacific Orange (clone
RA3-6B2) were from Invitrogen. Negative controls were
performed using isotype control antibodies. The gating
scheme was used in flow cytometric analysis of mouse blood
and BM was performed as described previously (42).
Measurement of cholesterol uptake/efflux in macrophages
Cholesterol efflux was measured (41) in BM-derived macro-
phages from 11-HSD1-KO and C57BL/6J control mice,
generated as described previously (21). Briefly, BM was
flushed from femurs, and 4 
 105 cells/well were plated in 1
ml DMEM/F12 (Invitrogen) supplemented with 10% FCS,
500 U/ml penicillin, 500 U/ml streptomycin and 10% mono-
cyte-CSF-conditioned supplement from murine fibrosarcoma
cell (L929) cultures (the concentrations of cortisol and
cortisone in FCS at this concentration are below the limit of
detection and 0.5 nM, respectively; below the Km of the
enzyme). Cells differentiated into macrophages over 7 d with
medium changed every 3 d. Apolipoprotein AI (ApoAI)-
mediated cholesterol efflux was measured in macrophages
loaded with acetylated low-density lipoprotein (AcLDL) by
incubation with 50 	g/ml [3H]-cholesterol-AcLDL for 24 h,
then a further 24 h in the presence or absence of 10 	g/ml
human ApoAI. [3H]-cholesterol was measured in centrifuged
medium and in cells after lipids were extracted with hexane:
isopropanol (3:2 v/v). Total cholesterol was measured on
cellular lipids using an enzymatic assay (Boehringer, Ingel-
heim, Germany). The percentage of specific cholesterol
efflux was calculated [medium cholesterol/(medium choles-
terol  cellular cholesterol)] after subtraction of values for
ApoAI-free medium.
Statistics
Values are expressed as means  se. Statistical analysis was
performed using Student’s t test, 1-way ANOVA, 2-way
TABLE 4. Effect of 11-HSD1 deletion on functional responses of intact aortic rings from ApoE KO mice fed a chow or WD diet
Diet
Emax (% relaxation) Sensitivity (log IC50)
ApoE KO DKO ApoE KO DKO
Chow
ACh 80.2  8.5 90.1  2.8 7.86  0.21 7.89  026
SNP 106.9  1.9 106.0  2.8 7.88  0.18 7.88  0.02
WD
ACh 71.1  4.6 69.3  8.5 7.9  0.2 7.7  0.4
SNP 115.4  5.6 104.7  2.5 7.9  0.1 8.2  0.1
Data are expressed as means  se. Chow data show the effect of 11-HSD1 deletion on functional responses of intact aortic rings from
ApoE-KO mice fed a chow diet; n 5. WD data show the effect of 11-HSD1 deletion on functional responses of aortic rings from apoE/ mice
fed a WD for 12 wk; n  6. Emax, maximum response; ACh, acetylcholine; SNP, sodium nitroprusside.
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Figure 3. 11-HSD1 deletion attenuates macrophage and T-cell infiltration in atherosclerotic lesions. A) ApoE-KO and DKO
mice (4.5 mo old) were fed WD for 14 wk, and Mac-2 or CD3 immunoreactivity was detected in the intimal lesion and the
underlying media of innominate arteries. B) Cell numbers were quantified absolutely or normalized to the area of the lesion
and media to give cell density (cells/mm2). Macrophage infiltration was unaltered in the lesions and media of DKO mice, when
matched for lesion area. C) However, the overall numbers of macrophages were reduced in the lesions of DKO mice. D, E) T-cell
infiltration (cells/mm2; D) or absolute T-cell numbers (E) were reduced into the lesions in DKO mice, but were unaltered in
the media (n5–7/group). Original view 
40. *P  0.05, **P  0.01, ***P  0.001 compared with ApoE-KO.
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ANOVA, or repeated-measures ANOVA, followed by Tukey
post hoc test, as appropriate. Values of P  0.05 were consid-
ered statistically significant.
RESULTS
11-HSD1 deficiency or inhibition attenuates
atherosclerosis in ApoE-KO mice
WD-fed ApoE-KO mice had extensive atherosclerotic le-
sions in the aortic arch and its major branches; narrowing
was most severe in the innominate artery (Fig. 1Ai).
Innominate artery lesions in WD-fed ApoE-KO mice were
complex, with fibrous caps comprising smooth muscle, col-
lagen, and elastin overlying areas of lipid deposition with
evidence of cholesterol crystal formation (Fig. 1Aii–iv).
Administration of a selective 11-HSD1 inhibitor to
WD-fed ApoE-KO mice for 8 wk reduced atheroscle-
rotic lesion size in all major (aortic arch, common
carotid, innominate) arterial territories examined (Fig.
1Ai). The maximum cross-sectional narrowing of the
innominate artery was significantly attenuated by 11-
HSD1 inhibition (Fig. 1B). Interestingly, 11-HSD1
inhibition for 8 wk improved markers of plaque stability
(Fig. 1C), with significantly more lesional collagen,
smaller areas devoid of cells or collagen (probably
reflecting extracellular lipid pools), and no increase in
smooth muscle cells (Fig. 1C).
The atheroprotective effects of 11-HSD1 inhibitors
Figure 4. Effect of 11-HSD1 deficiency on inflammatory monocytes (7/4hiLy6GCD11b) and neutrophils (7/4Ly6GCD11b)
in blood, BM, and spleen. DKO and ApoE-KO mice (4 wk old) were fed chow diet or WD for 14 wk, and then monocyte and
neutrophil numbers in the blood (A), BM (B), and spleen (C) were quantified by flow cytometric analysis (n5–21/group).
*P  0.05, **P  0.01 for effects of genotype; †P  0.05 for effects of diet.
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were recapitulated in genetic deficiency of 11-HSD1,
confirming on-target actions. Thus, in WD-fed DKO
mice, the area of the innominate artery affected by
atherosclerotic lesions was strikingly reduced compared
to ApoE-KO controls (Fig. 2A, C). WD-fed 11-HSD1/
(het) mice also had reduced atherosclerotic lesions at the
innominate artery, showing that partial 11-HSD1 defi-
ciency is also protective against severe atherosclerosis (Fig.
2A). Reduced lesion size in het and DKO mice was
accompanied by an increase in luminal area (Fig. 2A).
Reduced lesion size with 11-HSD1 deficiency is not
due to improvements in metabolic cardiovascular risk
factors or endothelial function
Systemic risk factors contribute to atherosclerosis, and
11-HSD1 inhibition/deletion reduces several of these
(obesity, glucose intolerance, and dyslipidemia) in
high-fat dietary obesity in mice (14–16) and humans
with type 2 diabetes (17). However, although WD
feeding caused modest weight gain, there were no
major differences between DKO and ApoE-KO mice in
food intake or body weight (Table 2); if anything, DKO
mice were slightly heavier. Notably, 11-HSD1 defi-
ciency on the ApoE-KO background did not affect
plasma cholesterol and triglyceride levels in chow-fed
mice, or the marked elevation of cholesterol on WD,
although the WD-induced elevation of plasma triglyc-
erides was attenuated in DKO mice (Table 2). More-
over, short-term (8 wk) 11-HSD1 inhibition in WD-fed
ApoE-KO mice did not alter fasting plasma cholesterol,
triglyceride, or NEFA levels (Table 3), while reduced
lesion size in WD-fed 11-HSD1 hets was associated
with higher cholesterol (34.42.5 mM) and triglycer-
ide (2.900.30 mM) levels. Thus, the development of
smaller lesions in mice with 11-HSD1 deletion or
inhibition is independent of lipid lowering. Similarly,
11-HSD1 inhibition did not affect fasting plasma
glucose or insulin levels in ApoE-KO mice (Table 3),
suggesting that the protection against lesion formation
is not due to improved glycemia on this strain back-
ground and diet.
Endothelial dysfunction may contribute to athero-
sclerosis. Aortic rings from DKO mice and ApoE-KO
controls, whether fed normal chow or WD, showed iden-
tical acetylcholine-elicited endothelium-dependent vaso-
dilation (Table 4). There were also no differences by
genotype or diet in SNP-mediated vasodilation (Table 4).
Thus, changes in endothelial and vascular smooth muscle
function do not underlie atheroprotection.
Circulating glucocorticoid excess may contribute to
atherogenesis. However, basal plasma corticosterone
levels were similar in ApoE-KO (42.813.6 nM; n6)
and DKO (50.68.4 nM; n8) mice. As reported
previously (14), adrenal glands were heavier (P0.001)
in DKO (0.200.01 mg/g body wt; n6) than ApoE-KO
(0.140.01 mg/g body weight; n7) mice, reflecting
increased adrenal corticosterone production with 11-
reductase deficiency.
11-HSD1-deficiency modestly reduces inflammatory
cell infiltration of atherosclerosis
11-HSD1, encoding an exclusive reductase, is ex-
pressed in innate (monocytes and macrophages; refs.
20, 21, 39) and adaptive (T cells; ref. 22) immune cells;
Figure 5. DKO monocytes and neutrophils are recruited to sites of inflammation during sterile peritonitis induced in chow-fed
mice by thioglycollate. At 72 h postinjection of thioglycollate, peritoneal cells were lavaged and analyzed by flow cytometry.
Quantitative analysis of blood monocyte subsets (inflammatory 7/4hiLy6GCD11b monocytes, resident 7/4loLy6GCD11b
monocytes, and total monocytes; A); blood neutrophils (PMNs; 7/4Ly6GCD11b; B), monocyte subsets in the peritoneum
(C); peritoneal PMNs, macrophages (macs), and neutrophil:macrophage aggregate (F4/80Ly6GCD11b) monocytes
(monos; D); and PMNs in the BM (E); n  9–11/group. *P  0.05 vs. ApoE-KO.
8 Vol. 27 April 2013 KIPARI ET AL.The FASEB Journal  www.fasebj.org
both are implicated in atherosclerosis (2, 5, 43). This
enzyme activity was abolished in resident peritoneal
cells (macrophages and neutrophils) from mice with
11-HSD1 deletion (11-reductase activity: wild-type,
7.7 pmol/h/106 cells; 11-HSD1-KO, below the limit of
detection of the assay, 0.2 pmol/h/106 cells). Al-
though 11-HSD1 deficiency causes worsening of acute
inflammation in joints and peritoneum, there was no
evidence of worse chronic inflammation in atheroscle-
rotic plaques. Indeed, in DKO atherosclerotic plaques,
macrophage numbers were reduced overall (if unal-
tered per lesion area; Fig. 3B, C), and there was a 36%
reduction in CD3 T cells per lesion area (Fig. 3D, E).
Real-time PCR detected iNOS (marker for M1), Relm-
(Fizz-1), and mannose receptor (markers for M2) in
aortic lesions from ApoE/ and DKO mice, but there
was no difference by genotype (not shown), suggesting
no change in macrophage polarization with 11-HSD1
deficiency in this context. Reduced inflammatory cells
in atherosclerotic plaques could be due to reduced
circulating cells. In ApoE-KO controls, WD caused
monocytosis, a change associated with fewer monocytes
in BM and spleen, suggesting release from these stores
(Fig. 4A). In contrast, in DKO mice, the WD-induced
monocytosis was attenuated and WD increased the
number of monocytes in spleen and BM (Fig. 4B, C).
Although circulating neutrophils were unaffected by
diet or genotype, these cells were also increased by WD
in the BM and spleen of DKO mice, again suggesting
increased proliferation and/or retention (Fig. 4). In-
deed, DKO mice exhibited splenomegaly following
WD, while the spleen weights in ApoE-KO mice were
not increased by WD (Table 2). However, despite
reduced circulating monocytes in WD-fed DKO mice,
the 7/4hiCD11bLy6G (corresponding to Ly6Chi)
subset that accumulates in ApoE-KO atherosclerotic
plaques (44, 45) was similar in the blood and BM of
chow-fed DKO mice, suggesting little difference in
pathogenic cell numbers. Moreover, macrophages in
chow-fed DKO and ApoE-KO mice were recruited
similarly to the peritoneum following injection of thio-
glycollate (Fig. 5), confirming their ability to be re-
cruited to sites of local inflammation.
MCP-1 is the major macrophage chemoattractant in
atherosclerosis (46). On a chow diet, serum MCP-1 levels
were similar in DKO and ApoE-KO mice (Fig. 6A). WD
increased serum MCP-1 in ApoE-KO mice, but DKO
mice resisted this rise (Fig. 6A), affording an explana-
tion for the apparent retention of cells in DKO mouse
BM and spleen. Reduced elaboration of MCP-1 in
adipose tissue appeared to be responsible, at least in
part, because mesenteric fat MCP-1 mRNA levels were
reduced (Fig. 6B), whereas levels in liver were unaf-
fected (data not shown). This was not a general change
in adipose-derived chemokines since leptin mRNA did
not differ (DKO, 1.270.38; ApoE-KO, 1.240.23 arbi-
trary units). Despite lower MCP-1 mRNA levels in DKO
adipose tissue, aortic MCP-1 mRNA levels were elevated
Figure 6. Effect of 11-HSD1 deficiency on circulating MCP-1 and mesenteric adipose tissue MCP-1 mRNA expression and
mRNA expression of MCP-1, CCR2, CX3CR1, and VCAM-1 in the ascending aortas. ApoE-KO and DKO mice (4 wk old) were
fed chow diet or WD for 14 wk. A, B) Serum MCP-1 level (A) and MCP-1 mRNA expression levels in MesAT (B) were elevated
by WD in ApoE-KO control mice, but not in DKO mice. C, D) Furthermore, although aortic MCP-1 (C), and CCR2 (D) mRNA
levels were elevated by WD, there was no difference by genotype. E) CX3CR1 mRNA transcript levels in the aorta were unaltered
by genotype and diet. F) Aortic VCAM-1 mRNA levels were similar in ApoE-KO and DKO mice fed chow diet. However, while
WD increased VCAM-1 mRNA in ApoE-KO mice, there was no change in DKO tissue (n5–8/group). *P  0.05, **P  0.01
for effects of genotype; †P  0.05, ††P  0.01 for effects of diet.
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similarly by WD in DKO and control mice (Fig. 6C).
MCP-1 acts largely via CCR2, but CCR2 mRNA levels in
aorta were unaltered by genotype (Fig. 6D), as were
aortic levels of mRNA encoding CX3CR1 (Fig. 6E),
which is also key to monocyte chemotaxis into athero-
sclerotic lesions (42). Thus, differences in the local
vascular MCP-1/chemokine receptor system do not
appear to underpin reduced inflammatory cell infiltra-
tion in DKO atherosclerosis; rather this appears likely
to be due, in part, to reduced availability of MCP-1.
Cell adhesion molecules, notably VCAM-1, are in-
creased in atherosclerotic vessels and play a key role in
mediating infiltration of both monocytes and lympho-
cytes into the vasculature (47). Aortic VCAM-1 mRNA
levels were similar on chow diet (Fig. 6F) but, while WD
increased aortic VCAM-1 mRNA in ApoE-KO mice, this
rise did not occur in DKO mice (Fig. 6F). This was
specific to VCAM-1, since aortic ICAM-1 mRNA levels
were unaffected by 11-HSD1-deficiency or WD (data
not shown). This suggests that, over and above any
effects on inflammatory cell availability, the host vessel
is less effective in recruiting inflammatory cells in
11-HSD1 deficiency.
11-HSD1 deficiency increases macrophage
cholesterol efflux
Of course, 11-HSD1-deficient macrophages in DKO
atherosclerotic lesions might be more atherogenic,
especially as high doses of glucocorticoids reduce mac-
rophage cholesteryl ester hydrolysis and export (31), so
relative glucocorticoid deficiency might be anticipated
to promote cholesterol accumulation. However, uptake
of AcLDL (Fig. 7A), or oxidized LDL (data not shown),
was similar in 11-HSD1-KO and wild-type macro-
phages, and 11-HSD1 deficiency had no effect on
expression of scavenger receptor A (SR-A) mRNA, the
major mediator of cholesterol uptake (Fig. 7C), though
11-HSD1-KO macrophages had modestly elevated lev-
els of CD36 mRNA, which also mediates macrophage-
cholesterol influx. In contrast, 11-HSD1-KO macro-
phages showed greater ATP-binding cassette transporter
A1 (ABCA1)-dependent cholesterol efflux (Fig. 7B), with
significantly increased levels of mRNAs encoding the
major cholesterol efflux transporters and acceptor,
ABCA1, ATP-binding cassette transporter G1 (ABCG1),
and ApoE. Thus, 11-HSD1-deficient macrophages show
an intrinsic antiatherosclerotic balance of cholesterol
trafficking.
Atheroprotection occurs with 11-HSD1/ BM
transplantation
To determine whether 11-HSD1-deficient BM-derived
cells are also intrinsically atheroprotective, ApoE-KO
recipient mice were lethally irradiated, and BM was
transplanted from either ApoE-KO or DKO mice. Fol-
lowing reconstitution, body and organ weights, plasma
lipids, and circulating blood leukocyte numbers were
not different between the groups, nor did hematopoi-
etic 11-HSD1 deficiency affect monocyte and neutro-
phil numbers in the BM and spleen (Table 5). However
in ApoE-KO mice, innominate artery atherosclerotic
lesion volume, assessed by OPT (38), and lesion cross-
sectional area were significantly reduced by transplan-
tation with DKO BM (Fig. 8), compared to lesions in
ApoE-KO mice transplanted with autologous ApoE-KO
BM. Macrophage infiltration into ApoE-KO atheroscle-
rotic lesions was unaffected by deletion of 11-HSD1 in
BM cells (data not shown), similar to global 11-HSD1-
deficiency. Thus, atheroprotection is mediated by 11-
HSD1-deficient BM-derived cells.
DISCUSSION
11-HSD1 deficiency or inhibition substantially re-
duces atherosclerosis in ApoE-KO mice. The effect was
clearcut, was similar with short-term selective inhibition
or genetic deficiency of 11-HSD1, and involved both a
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reduction in atherosclerotic lesion volume and, cru-
cially, an increase in the vessel lumen. Partial deficiency
of 11-HSD1 was also atheroprotective. Despite theo-
retical concerns of worse lesional inflammation, 11-
HSD1 deficiency was accompanied by no increase in
macrophages and reduced T-cell infiltration. There was
also an improvement in histological lesional stability
with increased fibrosis, plausibly reflecting attenuated
glucocorticoid-mediated inhibition of collagen biosyn-
thesis (48). Atheroprotection did not require improve-
ments in metabolic cardiovascular risk factors. Instead,
11-HSD1-deficient BM cells were responsible for
atheroprotection, plausibly at least in part because they
exhibit an atheroprotective phenotype of enhanced
cholesterol export.
The anticipated increase in lesional inflammation
with 11-HSD1 deficiency was not seen, with fewer T
cells and no increase in macrophages per lesional area,
plausibly due to lower circulating MCP-1 and less aortic
VCAM-1. Physiological glucocorticoids increase VCAM-1
via stimulation of mineralocorticoid receptors (which are
high-affinity sites for corticosterone in the absence of high
expression of 11-HSD type 2) in mouse aortic endothe-
lial cells (49), affording a possible explanation to contrast
with the effects of high doses of synthetic glucocorticoids
which act via glucocorticoid receptors to reduce endothe-
lial VCAM-1 transcription in vitro (50), while glucocorti-
coid receptor antagonists elevate VCAM-1 mRNA (51).
Perhaps surprisingly, there was little alteration in
circulating lipids to explain 11-HSD1 deficiency/inhi-
bition-mediated atheroprotection on the ApoE-KO
background. This may reflect the already markedly
hyperlipidemic state of this strain and/or the only
marginally obesogenic effect of WD—the beneficial
effects of 11-HSD1 deficiency/inhibition on cardio-
vascular risk factors predominantly occur in obesity (16,
17). 11-HSD1 inhibition/deficiency also ameliorates a
number of cardiovascular risk factors that are likely to
add to the atheroprotective benefits in wild-type ro-
dents and perhaps humans.
TABLE 5. Physiological characteristics, metabolic parameters, and immune cell phenotyping in ApoE-KO mice transplanted with ApoE-KO
or DKO BM cells
Parameter ApoE-KO BM ¡ ApoE-KO DKO BM ¡ ApoE-KO
Body weight (g) 32.4  2.2 36.4  2.6
Subcutaneous adipose tissue weight, absolute weight (mg) 809.7  249.5 1106.4  218.2
Epididymal adipose tissue weight, absolute weight (mg) 1091.3  317.2 1481.3  285.7
Mesenteric adipose tissue weight, absolute weight (mg) 364.1.3  70.9 606.1  135.0
Spleen weight ratio (mg/g BW) 4.56  0.41 4.51  0.73
Thymus weight ratio (mg/g BW) 1.12  0.17 0.92  0.16
Heart weight ratio (mg/g BW) 4.88  0.44 4.68  0.38
Left kidney weight ratio (mg/g BW) 6.19  0.41 5.65  0.23
Monocytes in blood (105 cells/ml) 10.8  1.7 10.9  1.7
Neutrophils in blood (105 cells/ml) 22.3  6.5 16.2  2.9
T lymphocytes in blood (105 cells/ml) 16.6  1.8 14.7  1.0
B lymphocytes in blood (105 cells/ml) 69.4  4.2 58.7  7.8
CD4511-HSD1 in blood (105 cells/ml) 60.5  10.6 3.2  0.7***
BM monocytes (105 cells/femur) 7.1  2.3 8.3  1.9
BM neutrophils (105 cells/femur) 35.8  11.8 53.2.14.4
BM CD4511-HSD1 (105 cells/femur) 50.0  16.2 1.8  0.4*
Splenic monocytes (105 cells/femur) 5.2  1.7 9.2  3.2
Splenic neutrophils (105 cells/femur) 6.2  1.4 9.6  2.6
Splenic T lymphocytes (105 cells/ml) 10.0  2.8 12.1  4.9
Splenic B lymphocytes (105 cells/ml) 22.5  7.3 24.2  8.8
Data are expressed as means  se; n  5/group. BW, body weight. ***P  0.001 vs. ApoE-KO BM ¡ ApoE-KO.
Figure 8. 11-HSD1 deletion in BM cells re-
duces atherosclerotic lesion size. Lethally irra-
diated ApoE-KO recipient mice were reconsti-
tuted with BM from ApoE-KO mice or DKO
mice and fed WD for 12 wk. Formalin-fixed
innominate arteries underwent OPT scanning.
Analysis of lesion volumes (A) and lesion cross-
sectional area (B) in the innominate arteries
demonstrated that ApoE-KO recipient mice
reconstituted with DKO BM cells exhibited
significantly smaller lesions when compared to
ApoE-KO mice reconstituted with ApoE-KO
BM cells (n5/group). *P  0.05, **P  0.01
vs. ApoE-KO mice reconstituted with ApoE-KO
BM cells.
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11-HSD1-deficient macrophages were able more
efficiently to export cholesterol, an impact expected to
be even greater when ApoE is present (ApoE mRNA
levels were higher in 11-HSD1-KO macrophages), since
ApoE is a key atheroprotective VLDL cholesterol trans-
porter with anti-inflammatory effects (52, 53). This sug-
gests that 11-HSD1 inhibitor-mediated atheroprotection
may extend to models of atherosclerosis expressing ApoE
and perhaps to humans. Notably, the atheroprotective
effect was seen with 11-HSD1 deficiency restricted in
transplanted BM, implying a key role for 11-HSD1-
deficiency in BM-derived cells over and beyond any
effects on host metabolism or the aortic milieu per se.
Overall, this study localizes the atheroprotective effects
of 11-HSD1 deficiency/inhibition to 11-HSD1 defi-
ciency in BM. This is very likely to be mediated by
leukocytes, e.g., changes in macrophages, but further
work is required to characterize which BM-derived
leukocytes are responsible. These results support the
clinical development of selective inhibitors of 11-
HSD1 as a novel multimodal treatment for atheroscle-
rosis and lesional inflammation over and above their
role in metabolic disease, from which the major cause
of mortality is atherosclerotic disease.
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